Table 1 Baseline characteristics of the study population (n = 28)
From: Outcome of adalimumab monotherapy in paediatric non-infectious uveitis
Characteristic | n (%) |
|---|---|
Gender, Female, n (%) | 15 (53.6) |
Ethnicity, n (%) | |
White-British | 24 (85.7) |
Others | 4 (14.3) |
Age at diagnosis of uveitis, years median,(IQR) | 5.6 (6.5) |
Anatomical distribution of uveitis, n (%) | |
Anterior | 24 (82.8)* |
Intermediate | 5 (17.2)* |
Presentation of uveitis, n (%) | |
Symptomatic | 3 (10.7) |
Asymptomatic | 25 (89.3) |
Laterality, n (%) | |
Bilateral | 21 (75.0) |
Unilateral | 7 (25.0) |
Underlying diagnosis, n (%) | |
JIA | 15 (53.6) |
Idiopathic | 13 (46.4) |
ANA positivity, n/N ( %) | 9/11 (99%) |
Duration of total adalimumab therapy (months), median (IQR) | 34.5 (41.25) |
Duration of adalimumab monotherapy (months), median, (IQR) | 15 (18.75) |